Innate Pharma partners with Sobi to license lacutamab in T-cell lymphoma for USD 75 million upfront
XLV•Innate Pharma and Sobi strike lacutamab partnership
- Innate Pharma struck a strategic partnership with Sobi to advance lacutamab in T-cell lymphoma, targeting a Phase 3 confirmatory study in CTCL.
- Innate will run the TELLOMAK-3 trial to support a planned accelerated approval filing in Sézary syndrome.
- Sobi will get exclusive global commercialization rights upon potential accelerated approval, with an option to take full global development rights after positive Phase 3 results.
- Sobi will pay USD 75 million at closing; Innate can earn up to USD 40 million in near-term development milestones tied to Sézary syndrome.
- Deal includes up to USD 465 million in option, regulatory, and commercial milestones, with tiered double-digit royalties on net sales.
